Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 25 mg - 103 EUR
  • 100 mg - 309 EUR
  • 250 mg - 618 EUR

Lapatinib ditosylate

Lapatinib is an orally available small molecule that targets the tyrosine activity of the erbB1 and erbB2 (Her2) receptors. It is used to treat breast cancers and other solid tumours.

catalogue number: L047
synonyms: Tykerb, GW-572016
CAS: 388082-78-8
MW: 925.46 g/mol (ditosylate)

References
Oncogene. 2002 Sep 12;21(41):6255-63. PMID: 12214266
Cancer Res. 2004 Sep 15;64(18):6652-9. PMID: 15374980
EGFR kinase domain complexed with GW572016 PDB: 1XKK

Prices
  • 5 mg - 220 EUR
  • 25 mg - 880 EUR
  • 100 mg - 2640 EUR

Lestaurtinib

Lestaurtinib is a multi targeted tyrosine kinase inhibitor. In preclinical studies, it was shown to inhibit FLT3 at nanomolar concentrations, prompting its rapid development as a potential agent for treating AML. Phase I studies have shown it to be an active agent, particularly when used in combination with cytotoxic drugs. It is currently undergoing Phase II and Phase III studies in patients with FLT3-ITD AML.

catalogue number: L100
synonyms: CEP-701, KT-5555
CAS: 111358-88-4
MW: 439.46 g/mol

References
Cancer Res. 1999 May 15;59(10):2395-401. PMID: 10344749
Expert Opin Investig Drugs. 2010 Mar;19(3):427-36. PMID: 20141349

Prices
  • 5 mg - 60 EUR
  • 25 mg - 240 EUR
  • 100 mg - 720 EUR

LBH-589

Panobinostat is one of the most widely studied anti-cancer agents, with extensive pharmacokinetic, pharmacodynamic and dose-finding data for a broad variety of hematologic and solid tumors. It has also demonstrated favorable clinical activity against various hematologic malignancies, most notably lymphomas and myeloid malignancies, in Phase I and II studies.

catalogue number: L048
synonyms: panobinostat
CAS: 404950-80-7
MW: 349.43 g/mol

References
Cancer Res. 2006 Jun 1;66(11):5781-9. PMID: 16740717
Future Oncol. 2009 Jun;5(5):601-12. PMID: 19519200

Prices
  • 5 mg - 85 EUR
  • 25 mg - 340 EUR
  • 100 mg - 1020 EUR

Linsitinib

Linsitinib has been developed as a small-molecule inhibitor of IGF-1R and IR kinases, with IC50 values of 35 nM and 75 nM, respectively. Linsitinib potently and selectively inhibits autophosphorylation of both human IGF-1R and IR in cells, displays in vitro antiproliferative effects in a variety of tumor cell lines and robust in vivo anti-tumor efficacy in a xenograft model. It undergoes clinical trials as a drug against several cancer types including adrenocortical, lung and ovarian carcinomas.

catalogue number: L168
synonyms: OSI-906, OSI 906AA
CAS: 867160-71-2
MW: 421.51 g/mol

References
Future Med Chem. 2009 Sep;1(6):1153-71. PMID: 21425998
Mol Cancer Ther. 2010 Oct;9(10):2652-64. PMID: 20924128
Cancer Treat Rev. 2012 Jun;38(4):292-302. PMID: 21907495